Sign inCreate account

Report workspace tools

NCT03510390COMPLETEDanonymous

Metformin in Head and Neck Squamous Cell Carcinoma: A Window of Opportunity Study to Assess the Effect on Tissue Oxygenation

Sponsor

Source record

Insel Gruppe AG, University Hospital Bern

Phase

Source record

NA

Modality

AI-normalized

small molecule

Target

AI-normalized

Head and Neck Squamous Cell Carcinoma

Indication / condition

AI-normalized

Head and Neck Cancer

Intervention

Source record

Metformin

Source & freshness

Source record

NCT ID

NCT03510390

Original source

ClinicalTrials.gov

Source last updated

Nov 18, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03510390

Title

Metformin in Head and Neck Squamous Cell Carcinoma: A Window of Opportunity Study to Assess the Effect on Tissue Oxygenation

Sponsor

Insel Gruppe AG, University Hospital Bern

Status

COMPLETED

Phase

NA

Condition raw

Head and Neck Cancer

Condition normalized

Head and Neck Cancer

Modality raw

Head and Neck Cancer

Modality normalized

small molecule

Target raw

Head and Neck Squamous Cell Carcinoma

Target normalized

Head and Neck Squamous Cell Carcinoma

Interventions

Metformin

Public preview

Source record

This study investigates the effect of Metformin on tissue oxygenation in patients with oral cavity squamous cell carcinoma. The trial aims to establish whether Metformin can reduce hypoxia in tumor tissues, potentially improving treatment outcomes and response to radiation therapy.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Metformin in Head and Neck Squamous Cell Carcinoma: A Window of Opportunity Study to Assess the Effect on Tissue Oxygenation

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03510390

Status

COMPLETED

Phase

NA

Sponsor

Insel Gruppe AG, University Hospital Bern

Executive brief

Investment-Ready Snapshot

This study investigates the effect of Metformin on tissue oxygenation in patients with oral cavity squamous cell carcinoma. The trial aims to establish whether Metformin can reduce hypoxia in tumor tissues, potentially improving treatment outcomes and response to radiation therapy.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 18, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03510390

Indication

Head and Neck Cancer

Modality

small molecule

Target

Head and Neck Squamous Cell Carcinoma

Intervention

Metformin

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.